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THE aim of this study was to investigate the pyrogenic
activity of factor(s) released by rat peritoneal
macrophages following a brief stimulation with LPS. The
effect of this factor on the number of circulating
leukocytes and serum Fe, Cu and Zn levels, was also
evaluated. The possibility that the content of interleukin
(IL)-I, IL-6 and tumour necrosis factor (TNF) in the
supernatant could explain the observations was investi-
gated. Supernatant produced over a period of I h by
peritoneal macrophages, following a 30 rain incubation
with LPS at 37C, was ultrafiltered through a 10 000 MW
cut-off Amicon membrane, sterilized, and concentrated
2.5, 5, 10 and 20 times. The intravenous (i.v.) injection of
this supernatant induced a concentration-dependent fe-
ver in rats with a maximal response at 2 h. The pyrogenic
activity was produced by macrophages elicited with
thioglycollate andby resident cells. The supernatants also
induced neutrophilia and reduction in Fe and Zn 6 h after
the injection. Absence of activity in boiled supernatants,
or supernatants from macrophages incubated at4C with
LPS, indicates that LPS was not responsible for the activ-
ity. In vitro treatment with indomethacin (Indo),
dexamethasone (Dex), or cycloheximide (Chx) did not
modify the release of pyrogenic activity into the
supernatant or its effects on the reduction in serum metal
levels. Although Chx abolished the production of
mediator(s) inducing neutrophilia, and Dex reduced the
induction of IL-I[, TNF and Ib6, injection of the highest
concentration of these cytokines detected in the
supernatants did not induce fever. In vtvo treatment with
Dex, but not Indo, abolished the fever induced by the
supernatant. These results suggest that macrophages con-
tain pre-formed pyrogenic mediator(s), not related to IL-
1, IL-6 or TNF, that acts indirectly and independently of
prostaglandtn. It also seems likely that the pyrogenic
activity is related to the factor responsible for the reduc-
tion of serum Fe and Zn levels, but not the neutrophilia.
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Introduction
Exogenous pyrogens such as bacterial endotoxin
(lipopolysaccharide, LPS) initiate a complex host
response which includes fever, neutrophilia and
changes in circulating glucocorticoid, glycoproteins
and serum metal levels, collectively called the acute-
phase reaction (APR). It is thought that LPS-induced
APR is caused by the release of cytokines into circu-
lation by several cell types including macrophages,
endothelial cells and fibroblasts. Many of these
cytokines, including interleukin-1 (IL-1), interleukin-
6 (IL-6), tumour necrosis factor (TNF), interleukin-8
(IL-8) and macrophage inflammatory protein-1 (MIP-
1), generally known as endogenous pyrogens (EP)
can induce fever when injected into experimental
animals and humans (see Reference 1 for a review).
Although all endogenous pyrogens can induce fever
the real role of each in the febrile response is not
clearly established.
It has been suggested that IL-1 (largely IL-I) is a
primary mediator of fever since peripheral or central
injection of this cytokine induces fever in different
species.
2-4 In addition, antiserum to IL-I prevents
the increase in body temperature and plasma IL-6
activity induced by intraperitoneal (i.p.) injections of
LPS in rats. However, there is little data demonstrat-
ing an elevation of IL-I[ in the plasma of febrile
animals and no increase in this cytokine was de-
tected in the cerebrospinal fluid of cats or in the
hypothalamus of rats after peripheral injection of
LPS. An increased synthesis of ,IL-I[ in the
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hypothalamus of rats was observed by using doses
of endotoxin that in terms of fever induction are
supra-maximal.
8
Recent studies in guinea-pigs and rats have
shown an increase in intrahypothalamic concentra-
tions of IL-6- and TNF-like activity during LPS-in-
duced fever. In spite of a strong correlation between
plasma IL-6 activity and increase in the body tem-
perature in guinea-pigs, there was no correlation
between fever and plasma TNF, or between fever
and IL-6 or TNF in the hypothalamic perfusate. In
rats, the hypothalamic infusion of IL-6, but not TNF,
at a rate that would mimic the amount of cytokine
activity found in the anterior hypothalamus during
LPS-induced fever, was effective in inducing an in-
crease in body temperature.
Data from many studies suggest that the first
cytokine to increase in plasma after LPS injection in
different animal species is TNF9-11 but its role in fever
is still unresolved. Intravenous infusions of TNF in
humans, or bolus injection of this cytokine in rats
and other species, result in fever.4,1,1-1 Furthermore,
pre-treatment of rabbits with antiserum to TNF inhib-
its LPS-induced fever.5 However, recent studies at-
tribute to TNF the role of an endogenous cryogen,
rather than an endogenous pyrogen, since antiserum
to TNF has been shown to increase LPS-induced
fever in rats. 16-19
Interleukin-8 is a cytokine released by a wide
variety of cell types upon exposure to inflammatory
stimuli or endogenous mediators such as IL-1 and
TNF’-’ and has been shown to induce fever after
central administration in rats. Unlike the response to
other cytokines, the febrile response induced by IL-
8 is not dependent on prostaglandin synthesis.’,’
Macrophages represent one of the main sources of
known cytokines’s and have also been shown to
release a chemotactic factor that specifically induces
neutrophil migration.
6 This chemotactic substance,
macrophage-released neutrophil chemotactic factor
(MNCF), is released by rat peritoneal macrophages
following a brief in vitro stimulation with
heterologous serum, LPS, TNF(z or IL-I.
7- This
chemotactic factor is distinguishable from other
known chemotactic agents/or cytokines and acts
directly.
Based on the ability of macrophages to release a
neutrophil chemotactic substance different from the
known cytokines, and because of the uncertain role
of known cytokines in the genesis of fever, the
purpose of this study was to investigate whether this
factor could induce fever and other APR components
such as changes in circulating white blood cells and
the concentration of serum metals. In addition, the
concentration of IL-I, TNF and IL-6 released by
macrophages during a brief incubation with LPS was
determined as well as the effect of in vitro and in vivo
treatment with steroidal and non-steroidal anti-
inflammatory drugs and protein synthesis blockers
on the release and action of the factor(s).
Material and Methods
Animals: Male Wistar rats weighing 180-200 g were
housed at 24 _+ lC with 12 h light/dark cycle, with
lights on at 0600, and given water and food ad
libitum.
Preparation of the supernatantfrom LPS-stimulated
macrophage monolayers: The supernatant was
prepared using a process similar to that described
previously by Cunha and Ferreira. ’9 Briefly, 4 days
before the harvest of peritoneal macrophages, rats
received an intraperitoneal injection of 10 ml of
3% thioglycollate. To evaluate possible effects of
thioglycollate, an equal number of macrophages
from non-injected animals were used in some experi-
ments. Peritoneal cells were harvested, using 10 ml
of RPMI 1640 medium (pH 7.4) containing 5 U/ml
heparin, and incubated in culture dishes for 1 h at
37C. To discard the non-adherent cells, the
monolayers were washed three times with phos-
phate buffered saline (PBS). Adherent cells in two or
three plates of each treatment were scraped using a
rubber policeman, resuspended in media, diluted in
Turk’s stain, and counted in a Neubauer chamber.
The differential cell count was performed as de-
scribed previously by Souza and Ferreira’7 and cellu-
lar viability was tested using 1% eosin y.3,. The
monolayers consisted of 95% macrophages, resulting
in a total of 0.6-1.0 x 107 viable cells/plate. The
cells were incubated with LPS (10gtg of
lipopolysaccharide E. coli 0111:B4/ml of RPMI) for
30 min at 37C. The monolayers were then washed
three times with PBS and incubated with 5 ml of
medium without LPS, for I h at 37C. To evaluate the
effect of the incubation temperature on the release of
substances, some experiments were conducted at
4C after adherence of the cells. The supernatant was
ultrafiltered with an Amicon YM 10 membrane, the
retained portion was resuspended in the saline for
intravenous injections or lyophilized and stored at
-20C for cytokine assays. To discount the possibility
of contamination with LPS, supernatant (10 times
concentrated) and LPS were boiled for 30 min. The
supernatants were sterilized with a 0.22 gtm
(Millipore Corporation, Bedford) membrane prior to
intravenous (i.v.) injections.
Treatment of macrophage monolayers with
dexamethasone, cycloheximide and indomethacin:
Macrophage monolayers were incubated with 3 or
9gtg/ml dexamethasone (Dex), 3 and 91.tg/ml
cycloheximide (Chx) or 0.5 and 2 lag/ml
indomethacin (Indo) for 60, 30 or 15 min respec-
tively, before LPS addition. During and after LPS
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stimulation, the monolayers were incubated with
RPMI medium containing the same concentration of
the drugs. Control supernatants had the drugs added
at the end of the incubation period. The preparation
of the supernatant for injection was carried out as
described above.
Temperature measurements: Rectal temperature was
measured by inserting a thermistor probe (Y.S.I. nr.
402) 3 cm into the rectum. The animals were picked
up gently and held manually during the temperature
measurements. This procedure was performed at
least twice on the day before the experiment to
minimize stress-induced temperature changes sec-
ondary to handling. On the day of the experiment,
the basal temperature of each animal was determined
four times, at 30 min intervals, before any injection.
The experiments were carried out between 0800
and 1700 h at 28 _+ 1C, which is considered the
thermoneutral zone for rats. 33
Leukocyte counts and serum metal assays: Two, 6
and 24 h after the i.v. injection of pyrogenic stimuli,
animals were anaesthetized with pentobarbitone
sodium (40 mg/kg, i.p.) and blood samples were
taken from the abdominal aorta for haematological
determination. Total and differential cell counts were
performed and the results are reported as the number
of neutrophils per ml of blood, iv Before the serum
metal assays, serum was prepared by adding the
same volume of trichloroacetic acid 20% and heating
at 90C for 15 min. The mixture was centrifuged at
1000g by 15 min and the Fe, Zn and Cu levels were
measured in the supernatant using atomic absorption
spectrophotometry.
Experimentalprotocols: The rectal temperature of the
rats was measured at 30 min intervals for 2 h before,
and up to 6 h after i.v. injections of pyrogens. LPS
(0.5 lttg/kg), murine recombinant IL-I[ (2.5 btg/kg) or
supernatants were administered intravenously in the
penial venous sinus in a volume of 0.2 ml. The effects
of steroidal and non-steroidal anti-inflammatory
drugs on temperature responses to i.v. injections of
the supernatant, LPS and IL-I were also investi-
gated. Indo (2 mg/kg, i.p.) and Dex (0.5 mg/kg s.c.)
were given 30 min and 1 h, respectively, before the
i.v. injection of supernatants. Control animals were
treated with the appropriate vehicle only. The pyro-
genic stimuli were injected at 1100 h.
Cytokine assays: Cytokine bioactivities were meas-
ured in supernatants from Dex-treated macrophages
and control supernatants. For these studies, the
supernatant was lyophilized and resuspended in
culture medium. IL-1 was assayed as described pre-
viously, using the D10(N4)M (D10) cell line. 34 Activity
was determined by comparison to the National Insti-
tute of Biological Standards and Controls (NIBSC)
interim standard for IL-I (lot. 86.552, 1 U 10 pg).
IL-6 was assayed using the B9 hybridoma5’6 as
described previously by Holt et al.7 For the assay, B9
cells were used 3-4 days after the last subculture.
Bioactivity was determined by comparison to a
recombinant IL-6 preparation provided by Dr L. A.
Aarden.8
TNF was assayed using L929 fibroblasts, using a
protocol adapted from Matthews and Neale.39 The
cells were maintained in DMEM supplemented with
5% FCS and 2 mM glutamine. Cells isolated with
0.25% trypsin, were seeded into microplates wells at
1 10 cells/wells, and cultured overnight with
200 pg/ml actinomicin D for 1 h before addition of
samples or controls. The TNF concentration was
determined by comparison to the NIBSC standard for
TNF0t (lot. 88/532). Cellular activity in all assays was
determined by monitoring metabolism of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide to its formazan product.4
Materials: Lipopolysaccharide from E. coli (0111:B4),
cycloheximide, glutamine, trypsin and MTT were
purchased from Sigma Chemicals and Co., USA;
thioglycollate from Difco Laboratories, USA; RPMI
from Gibco Laboratories, USA; heparin from Roche,
Brazil; yellow eosin from Merck; dexamethasone
(Decadronal) from Prodome, Brazil; and DMEM from
Northumbria Biologicals. Indomethacin was a gift
from Merck, Sharp & Dohme, Brazil. Recombinant
murine cytokines used to induce fever were IL-I
(lot. No. BN091), IL-6 (lot. No. BEIN3.19) and TNFx
(lot. No. CS184), all from R & D Systems, Inc.,
Minneapolis.
Statistical analysis: Febrile responses were assessed
by measuring the increases in rectal temperature and
are expressed as the difference between rectal tem-
perature before and at specified times after injection
of the pyrogenic stimuli. All data are expressed as the
mean _+ S.E.M. and were analysed using one-way
analysis of variance, followed by Tukey’s test, and a
level of significance at p< 0.05.
Results
Intravenous injection of supernatant from
thioglycollate-elicited macrophages stimulated in
vitro with LPS induced a concentration dependent
fever as illustrated in Fig. 1A. The i.v. injection of 2.5-
fold concentrated supernatant did not change the
rectal temperature of the animals, while 5-, 10- and
20-fold concentrated supernatant induced a consid-
erable febrile response which peaked at 2 h. Both 10-
and 20-fold concentrated supernatant, induce a
maximal response, although the response to the
higher concentration declined more rapidly. The 20-
fold concentrated supernatant was used in the re-
maining experiments. Induction of the macrophages
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with thioglycollate was not essential to the release of
pyrogenic factor(s) since supernatant from LPS-
stimulated resident macrophages induced fever with
similar time-course and magnitude (Fig. 1B) when
compared to the response induced by supernatant
FIG. 1. Panel A: concentration dependent febrile response induced by
supernatants from LPS-stimulated macrophages harvested from
thioglycollate-elicited cavities. Panel B: febrile response induced by
supernatant from thioglycollate or resident macrophages stimulated in vitro
wit LPS. In both panel A and B macrophages were incubated in vitro with
LPS for 30 min and supernatants were injected i.v. in concentrations
indicated in the Figure. Panel C: control groups received supernatant from
unstimulated macrophages, culture medium or saline. Each curve shows
means S.E.M. of rectal temperature changes. Basal rectal temperatures
(C) were: Panel A: (O), 37.6 0.10, n 7; (o), 37.4 0.18, n 7; (.),
37.3 0.10, n 8; (,), 37.8 0.17, n 4. Panel B: (O), 37.3 +/- 0.06,
n 8; (o), 37.4 +/- 0.07, n 6. Panel C: (El), 37.3 +/- 0.11, n 7; (I), 37.5
+/- 0.17, n 4; (7), 37.5 +/- 0.11, n 9. *Values significantly different from
saline, p <0.05.
from LPS-stimulated macrophages previously elicited
by thioglycollate. Injection of the medium,
supernatant from unstimulated macrophages or sa-
line, did not change the body temperature of the rats
(Fig. lC). LPS contamination was not responsible for
the supernatant-induced fever since supernatant
from LPS-stimulated macrophages cultured at 4C did
not induce fever. Furthermore, as shown in Table 1,
no change in body temperature was observed after
i.v. injection of supernatant boiled for 30 min. In
vitro treatment of macrophages with 3 or 9/.tg/ml
Dex, 3 or 9 ILtg/ml Chx or 0.5 or 2.0 ILtg/ml Indo did
not modify the pyrogenic activity of the supernatant
(Fig. 2).
Supernatant from LPS-stimulated macrophages,
harvested from thyoglycollate-elicited peritoneal
cavities, induced a significant neutrophilia and
reduction of the serum Fe level 2 and 6 h after
i.v. injection, while reduction of serum Zn levels
was evident only at 6h. On the other hand,
LPS caused neutrophilia 2 and 6h after i.v.
injection, while reduction of Fe and Zn levels
was observed only at 6 h. In both cases the observed
neutrophilia and reduction of serum metal levels
were more marked at 6 h (Table 1). Neither the
supernatant nor LPS induced any change of
the serum Cu level. Boiling diminished the
neutrophilia, abolished the reduction of the Zn level,
but did not modify the reduction of the Fe level
induced by the supernatant (Table 1).
Table 1. Changes in body temperature, circulating neutrophils, serum Fe and Zn levels induced by
saline, LPS, non-boiled and boiled supernatants from LPS-stimulated macrophages in rats
Pyrogenic stimulus Time Temperature Neutrophils Fe Zn
(h) change (C) (cells/ml.10-) (lg/100ml) (lg/100ml)
Saline 2 0.02 + 0.10 1.68 + 0.18 240.0 _+ 23.7 348.4 + 20.2
(1 ml/kg) 6 0.00+0.10 1.17+0.14 133.3+ 17.5 267.3+ 11.5
LPS 2 1.14 + 0.15" 5.75 + 0.37* 223.8 _+ 14.7 329.5 + 11.9
(0.5 g/kg) 6 0.13 + 0.21 6.84 + 0.77* 19.4 + 10.4" 147.0 + 23.1"
Non-boiled 2 1.02 + 0.06* 3.13 + 0.39* 106.5 + 7.8* 311.7 + 10.3
supernatant (10 x) 6 -0.08 + 0.05 9.10 + 1.18" 78.9 + 14.1" 202.1 + 14.1"
Boiled 2 -0.10 + 0.06** ND ND ND
supernatant (10 x) 6 -0.43 + 0.07 3.51 + 0.44** 16.7 + 3.6** 267.0 + 16.0"*
Macrophages from thioglycollate-elicited peritoneal cavities were stimulated in vitro with LPS for 30 min.
The supernatants were ultrafiltered with an Amicon YM-.10 membrane and resuspended in saline. Non-
boiled and boiled (30 min boiling period) supernatant was sterilized with a 0.22 lm membrane and
injected i.v. in a volume of 0.2 ml/rat. Values represent the mean + S.E.M. of each parameter observed
in 6-13 animals. ND Not done; *significantly different from saline; **significantly different from non-
boiled supernatant, p < 0.05.
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FIG. 2. Effect of Dex (Panel A), Chx (Panel B) and Indo (Panel C) upon
release of pyrogenic factor(s) from LPS-stimulated macrophages.
Macrophages were incubated with drugs before, during and after LPS
stimulation. Control supernatant had the highest concentration of the drug
added after the last incubation. The supernatants were injected as de-
scribed in the legend to Fig. 1. Each curve shows mean S.E.M. of rectal
temperature changes observed in 7-11 rats. Basal rectal temperatures
(C) were: Panel A: (O), 37.2 0.08; (1), 37.3 0.06; (/k), 37.2 +/- 0.05.
Panel B: (O), 37.3 +/- 0.05; (1), 37.3 +/- 0.04; (/k), 37.3 +/- 0.03. Panel C: (O),
37.3 +/- 0.06; (t), 37.2 +/- 0.04; (A), 37.3 +/- 0.05.
The neutrophilia, but not the reduction of serum
metal levels, induced by the supernatant was signifi-
cantly reduced when the macrophages were incu-
bated in the presence of Chx (Fig. 3). The treatment
of the macrophages with Dex or Indo did not sign-
ificantly affect the neutrophilia induced by
the supernatant 6 h after the injection (control
supernatant, 6.47 +_ 1.05; Dex, 9 l.tg/ml, 4.05 +_ 0.72;
Indo, 2 l.tg/ml, 8.45 _+ 1.17 neutrophils x 106/ml).
When rats were pretreated with Dex (0.5 mg/kg, s.c.)
1 h before the harvesting of the peritoneal
macrophages and all further steps of the supernatant
preparation were conducted in presence of 9 t.tg/ml
Dex, the magnitude of fever induced by the resulting
supernatant was similar to that induced by
supernatant from macrophages obtained from un-
treated animals (Fig. 4). Treatment of rats with Dex
(0.5 t.tg/kg, s.c.) inhibited febrile responses to i.v.
injection of LPS, IL-1[ and supernatant (Fig. 5). In
contrast, Indo (2 mg/kg, i.p.) significantly reduced
the febrile response to i.v. injections of LPS and IL-
1}, but did not modify the response induced by the
supernatant (Fig. 6). The treatment of animals with
Dex and Indo did not affect the neutrophilia or the
reduction of serum Fe and Zn levels induced by LPS
or supernatant.
The IL-1[, IL-6 and TNF bioactivities were meas-
ured in supernatants. Values varied quite widely
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FIG. 3. Effect of in vitro treatment with Chx on the release of factor(s) from LPS-stimulated macrophages, that induce neutrophilia (Panel
A) and changes in metal levels (Panel B). Blood samples were collected 6 h after the injections of supernatants from untreated (C) and treated
with Chx (3 and 9 l.tg/ml) macrophages (Chx). Control groups received saline (S). The bars represent the mean +/- S.E.M. of the neutrophil
number or metal levels. The number of animals per group is indicated above each bar. "Values different from saline; #Values different from
control supernatant, p < 0.05.
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FIG. 4. Effect of in vivo and in vitro Dex treatment on release of pyrogenic
factor by LPS-stimulated macrophages. Dex at 0.5 mg/kg was injected h
before harvesting of peritoneal macrophages. In all further steps of
supernatant preparation, macrophages were treated with 9 I.tg/ml Dex.
Control supernatant received Dex after the last incubation. Each curve
shows mean +/- S.E.M. of rectal temperature changes observed in 8-10
rats. Basal rectal temperatures (C) were: (O), 37.15 +/- 0.08; (o), 37.14 +/-
0.04.
between different supernatants and the highest val-
ues are shown in Table 2. Unlike the pyrogenic
activity Dex inhibited the release of these cytokines.
The injection of the mixture of murine recombinant
IL-I, TNF(x and IL-6 at the highest concentrations
found in the supernatants induced a maximal in-
crease in body temperature of 0.12 _+ 0.04C, 30 min
after injection, which was not significantly different
to saline treated controls (0.13 +_ 0.03C).
Discussion
This study shows that macrophages briefly stimu-
lated with LPS release a factor that induces an in-
crease in rectal temperature, neutrophilia and reduc-
tion in serum Fe and Zn levels, mimicking important
components of APR.
It is unlikely that these activities represent a non-
specific response due to contamination of the
supernatant with LPS since when the metabolic activ-
ity of the macrophages was reduced by cooling to
4C, they did not release pyrogenic factor(s), and
boiling the supernatant abolished the fever and Zn
reduction and reduced the neutrophilia. The release
of the pyrogenic factor(s) was not related to previous
thioglycollate stimulation, since supernatant from
LPS-stimulated resident macrophages also induced
fever.
The treatment of the cells, or rats acting as the
source of macrophages, with Dex did not modify the
pyrogenic activity, although production of IL-1, IL-6
and TNF was inhibited. Since glucocorticoids sup-
press the cytokine or LPS-stimulated production of
IL-1,
41 WNF,42 IL-6, IL-843 and MNCF9 these findings
from in vitro Dex treatment distinguish the pyrogenic
factor from other known pyrogenic or chemotactic
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FIG. 5. Effect of treatment with Dex on the increases in rectal temperature
induced by i.v. injection of LPS (Panel A), IL-11 (Panel B) or supernatant
(,Sup) from LPS-stimulated macrophages (Panel C). Animals were
pretreated with 0.5 mg/kg s.c. Dex, h before the injections of pyrogenic
stimuli. Control groups were pretreated with saline. Each curve shows
mean +/- $.E.M. of rectal temperature changes observed in 5-8 rats. Basal
rectal temperatures (O) were: (O) 37.3 +/- 0.06; (o), 37.2 +/- 0.08; (/), 37.2
+/- 0.06; (,), 37.2 +/- 0.05; (O), 37.0 +/- 0.08; (), 37.2 +/- 0.09. "Significantly
different from saline-treated animals, p < 0.05.
cytokines. In contrast, treatment of rats with Dex (0.5
mg/kg) inhibits fever induced by the supernatant or
IL-I.
The failure of Chx to inhibit the release of the
factor that induces fever and reduction of the serum
metal levels supports the hypothesis that this factor
is not produced following synthesis of cytokines,
though it did abolish the release of the factor that
induced neutrophilia. Moore et al.44 and Nordlund et
al.45 showed that Chx inhibits the production of EP
by rabbit granulocytes or human monocytes stimu-
lated with LPS or Staphylococcus albus. However,
this inhibition was related to activity observed
12-16 h after stimulation. Therefore, it is plausible
that macrophages release pre-formed factor. Similar
findings have been recently obtained by Won andPre-formedpyrogenic factor
1.5
1.0
0.5
1.5
1.0
0.5
1.5
1.0
0.5
-0.5
A
(C) Tris LPS 0.5 Ig/kg. i.v.
Indo 2 mg/kg, i.p. + LPS 0.5 Ig/kg. i.v.
/ Tris + IL-I 2.5 lg/kg, i.v. B , Indo 2 mg/kg, i.p. + IL-I 2.5 Ig/kg. i.v.
IEI Tris + Sup (10x), i.v.
Indo 2 mg/kg, i.p. + Sup (10x), i.v.
-1 0 2 3 4 5 6
Time (h)
FIG. 6. Effect of treatment with Indo on the increase in rectal temperature
induced by i.v. injection of LPS (Panel A), IL-1I] (Panel B) or supernatant
(Sup) from LPS-stimulated macrophages (Panel C). Animals were
pretreated with 2 mg/kg, i.p., Indo 30 min before the injection of pyrogenic
stimuli. Control groups received Tris buffer. Each curve shows mean
S.E.M. of rectal temperature changes observed in 5--9 rats. Basal rectal
temperatures (C) were: (O), 37.4 0.10; (o), 37.6 0.13; (L), 37.1
0.04; (,), 37.2 0.04; (r3), 37.3 0.04; (I), 37.3 0.05. "Significantly
different from Tris vehicle-treated animals, p < 0.05.
Table 2. Maximal concentration of IL-I}, IL-6 and TNFe in
supernatants from LPS-stimulated macrophages treated or not with
Dex.
Treatment IL-1 J} IL-6 TNF
(ng/ml) (ng/ml) (ng/ml)
None 6.8 + 0.45 10.17 + 0.00 12.5 + 0.23
Dex 2.3 + 0.19" 0.29 + 0.2* 2.3 + 0.52*
Macrophages were incubated with Dex (9 lg/ml) before, during and
after LPS stimulation. The supernatants were ultrafiltered in YM-10
Amicon membranes, lyophilized and stored at-20C until the day
of the assay, when they were resuspended in culture medium to
give a 10-fold concentrated solution. Values represent the
mean + S.E.M. (4-6 wells) cytokine concentration in the sample
with the highest level of cytokine. *Values significantly different from
untreated cells, p< 0.001.
Lin,46 using human monocytes. In this study human
monocytes, treated with Chx and stimulated with
polyribo-inosinic polyribocytidylic acid, released a
pyrogenic factor into the supernatant. These results
also show that different factors are responsible for
the observed fever and neutrophilia.
It is unlikely that prostaglandins are responsible for
the activities observed in the supernatant because
the treatment with Indo did not modify its
pyrogenicity or its ability to induce haematological
changes (data not shown). The rapid inactivation
after intravenous injections and the molecular weight
(<10 kDa) of eicosanoids also make this unlikely.
Although prostaglandins synthesized by monocytes/
macrophages, inhibit the production of cytokines,
including IL-1 and TNF,47’48 Indo did not affect the
pyrogenic activity of the supernatant.
Low concentrations of IL-lJ, IL-6 and TNFc were
found in the supernatant from LPS stimulated
macrophages. Pretreatment of macrophages with
Dex reduced these cytokine concentrations even
more. However, the concentrations of cytokines
necessary to induce fever of comparable magnitude
to the supernatant are considerably higher.49-51 A
synergistic effect of these cytokines does not fully
account for the observed febrile response, since the
i.v. injection of a mixture of these cytokines, in
the highest concentration found in the supernatants,
did not induce any change in rectal temperature.
The presence of cytokine precursors in the
supernatant cannot be discounted, since precursors
of IL-lot and [} were found in supernatant from
peritoneal macrophages after LPS stimulation. 5’,53
On the other hand, the results obtained with Indo
treatment suggest these precursors are not present
because their active products induce a febrile
response that is abolished by cyclooxygenase
inhibitors.
Because our results point to some factor(s) differ-
ent from the known pyrogenic cytokines we inves-
tigated the effect of anti-inflammatory drugs on the
febrile response induced by the supernatant. Con-
firming previous results Dex inhibited the fever in-
duced by LPS and IL-I[}. Similarly, supernatant in-
duced fever was inhibited by Dex, suggesting an
indirect mechanism, e.g. the release of pyrogenic
mediators. However, the treatment of animals with
Indo did not modify the fever induced by the
supernatant, while the febrile response induced by
LPS and IL-I} was partially inhibited. Many studies
have demonstrated that MIP-1 and IL-8 induce a
prostaglandin-independent febrile response. ’3,24,54
Thus, it is possible that these cytokines could be
involved in supernatant induced fever.
Two factors suggest the supernatant activity is
unlikely to be IL-8. Firstly, the relatively low concen-
tration of other cytokines produced during 30 min of
macrophage stimulation. Secondly, preliminary stud-
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ies, using ultrafiltration in YM 30 membranes, have
demonstrated that the MW of our pyrogenic factor is
above 30 kDa. All the pyrogenic cytokines released
by macrophages possess a molecular weight slower
than 30 kDa.
Kluger has stressed that although many cytokines
induce fever when injected into experimental ani-
mals or humans, the precise contribution of any EP
in naturally occurring fever has not yet been com-
pletely determined. This concept, together with evi-
dence for a pre-formed pyrogenic factor described
here, allow us to hypothesize that this factor may
represent a trigger for fever induction by promoting
the release of another pyrogenic mediator which acts
by a prostaglandin independent mechanism. A pos-
sible candidate is CRF, explaining the effectiveness of
glucocorticoids and the partial effectiveness of
cyclooxgynase inhibitors in the febrile response in-
duced in rats by IL-113 or LPS. These findings could
explain the inability of antipyretic drugs to abrogate
the fever response observed in a number of clinical
situations. Furthermore, the present study empha-
sizes the importance of macrophages as alarm cells55
because of their ability to react to foreign substances
and release mediators responsible for the initial sys-
temic and local events, such as fever, neutrophilia
and cell migration.3,56
In conclusion, the results presented here allow us
to suggest that macrophages contain pre-formed
pyrogenic substance(s) which are not related to IL-
l[3, IL-6 or TNF, and act indirectly and independently
of prostaglandin synthesis. It also seems likely that
the pyrogenic activity is related to the factor respon-
sible for the reduction of serum Fe and Zn levels, but
not the neutrophilia.
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